Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Zhujiang Hospital | OTHER |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | OTHER |
| Guangzhou Jeeyor Medical Research Co.,Ltd. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the role of continuous oxygen therapy combined with blue light deprivation in prevention and control of retinitis pigmentosa, in order to find a new strategy of treatment for retinitis pigmentosa.
Retinitis pigmentosa (RP) is one of of the major causes of blindness in ocular diseases.Up to now, the etiology of RP remained unclear, and there are no effective therapeutic methods. Several studies had showed that the retina of RP may be anoxic, and oxygen therapy, such as hyperbaric oxygen (hyperbaric oxygen, HBO) treatment, had shown a definite effect on RP. The investigators' previous researches also found that the retinal vessel oxygen saturation in patients with RP who were older than 40 years were significantly lower than normal controls, suggesting that oxygen may play an important role in the development of RP. Besides, many studies have revealed that blue light could damage retina pigment epithelium cells and photoreceptor cell specially. Therefore, investigators will combine continuous oxygen therapy and blue light deprivation therapy in the treatment for RP in this study, in order to find a new strategy of treatment for RP.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous Oxygen | Experimental | Continuous oxygen intake and routine drug treatment . |
|
| Blue Light Deprivation | Experimental | Wearing blue light-absorbing sunglasses at daily time and routine drug treatment |
|
| Continuous Oxygen Therapy Combined With Blue Light Deprivation | Experimental | Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment |
|
| control | Other | Routine drug treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Continuous oxygen | Drug | Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week; |
|
| Measure | Description | Time Frame |
|---|---|---|
| the percentage of patients preserved 80% of the initial visual acuity at 5 years follow-up. | at 5 years follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| ERG b-wave mean values | at 5 years follow-up | |
| Change of visual field | visual field | at 5 years follow-up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qianying Gao, PHD | Contact | 13751829105/18922103820 | gaoqy@mail.sysu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Qianying Gao, PHD | State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou | Guangdong | 510060 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| blue light-absorbing sunglasses | Device | Wearing blue light-absorbing sunglasses at daily time; |
|
| Compound thrombosis capsule sig: 1.5g/tid | Drug | Compound thrombosis capsule sig: 1.5g/tid |
|
| Ginkgo biloba pills sig: 300mg/tid; | Drug | Ginkgo biloba pills sig: 300mg/tid; |
|
| Vitamin B sig: 10mg/tid | Drug | Vitamin B sig: 10mg/tid |
|
| Vitamin AD sig: 1 tablet/tid | Drug | Vitamin AD sig: 1 tablet/tid |
|
| Fundus changes of fluorescence fundus angiography |
| at 5 years follow-up |
| Retinal vessel oxygen saturation | Retinal Oximetry | at 5 years follow-up |
| intra-ocular pressure | at 1, 2, 3, 4 and 5 years follow-up |
| blood pressure | at 1, 2, 3, 4 and 5 years follow-up |
| Finger pulse oxygen saturation | Finger pulse oximetry | at 1, 2, 3, 4 and 5 years follow-up |
| the mutant genes of retinitis pigmentosa | gene screening | at admission |
| ID | Term |
|---|---|
| D012174 | Retinitis Pigmentosa |
| ID | Term |
|---|---|
| D015785 | Eye Diseases, Hereditary |
| D005128 | Eye Diseases |
| D058499 | Retinal Dystrophies |
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D011947 | Receptors, Antigen, B-Cell |
| ID | Term |
|---|---|
| D007136 | Immunoglobulins |
| D012712 | Serum Globulins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D005916 | Globulins |
| D011946 | Receptors, Antigen |
| D011971 | Receptors, Immunologic |
| D011956 | Receptors, Cell Surface |
| D008565 | Membrane Proteins |
Not provided
Not provided